Bondics
Therapeutics
Precision Targeting Platform
for Oncology and Senescence
We develop integrated therapeutic and diagnostic technologies—including immune engagers, targeted radiotracers, and next-generation binding scaffolds—to detect, stratify, and eliminate disease-driving cells.
Immune Engagers
Targeted NK cell recruitment for selective elimination of disease-driving cell populations.
Radiotracers
Diabody-based molecular imaging for precision tumor detection and patient stratification.
Bicyclic Peptides
Conformationally constrained scaffolds with enhanced tissue penetration and target affinity.
Complex Disease.
Insufficient Tools.
Cancer and age-related diseases are driven by heterogeneous cell populations resistant to conventional detection and elimination strategies.
An Integrated Precision
Targeting Platform
We combine complementary technologies into a unified framework that addresses detection, stratification, and elimination.
TRK-001 — First-in-Class Tri-specific Killer Engager
Designed to selectively eliminate disease-driving senescent cells with high precision and sustained immune activation.
An Integrated Targeting Platform
Our platform integrates immune effector recruitment, target-specific binding, and diagnostic imaging to enable mechanistically driven therapeutic development.
Tri-specific Killer Engager (TriKE) Module
Engineered fusion proteins that bridge NK cells to disease-associated surface antigens, inducing potent and sustained cytotoxic responses.
Radiotracer (Diabody-Based Imaging) Module
Engineered diabody fragments for targeted molecular imaging enabling non-invasive quantification of target expression across tumor compartments.
Bicyclic Peptide Module
Conformationally constrained scaffolds engineered for high-affinity target binding with superior tissue penetration and protease resistance.
One integrated platform with three modality engines.
A Multi-Modal Precision Pipeline
Integrating detection, stratification, and elimination into a single development framework across three complementary programs.
Advance TRK-001
Progress lead TriKE program toward IND filing with preclinical package.
Optimize RT-101
Refine radiotracer pharmacokinetics and imaging window for clinical translation.
Expand BCP Library
Broaden bicyclic peptide targeting to additional oncology and senescence antigens.
Transforming Disease Treatment
Through Precision Targeting
Oncology
Targeting complex, antigen-heterogeneous tumors with high specificity through integrated detection, stratification, and immune-driven elimination strategies.
Fibrosis & Senescence
Eliminating senescent and fibrogenic cell populations that drive chronic disease progression and tissue dysfunction across multiple organ systems.
Next-Gen Therapeutics
Enabling entirely new therapeutic modalities through advanced targeting scaffolds, multispecific formats, and theranostic platform development.
Built by Experts in Immunology
and Molecular Engineering
Our team brings together deep expertise across immunology, protein engineering, and translational medicine, supported by advisors with experience in oncology, aging science, and drug development.
“To develop precision targeting platforms that redefine the treatment of complex diseases.”
Partner With Us
We are open to exploring additional collaboration opportunities aligned with our platform.
Want to join our team ? Please send us a message !
Bang Phlat, Bangkok, Thailand 10700